Tesamorelin vs. sermorelin: what TikTok gets wrong about peptide GH therapy

What did @grant.feltz actually say?

Grant Feltz positions himself as a peptide selector who helped a client named Steve get results in three months by picking the right growth hormone-releasing peptide. His core argument: tesamorelin is the aggressive fat-loss tool that "pushes your body to release growth hormone in a stronger way," while sermorelin is the gentle, long-term option that "reminds your body how to make growth hormone on its own." He recommends pairing tesamorelin with "the hard R" (presumably ipamorelin) and sermorelin with GHK-Cu. He closes by funneling viewers into a DM-based "protocol cheat sheet" from his one-on-one client practice.

He frames this as a simple decision tree: fat loss goes one way, recovery and anti-aging go the other. That framing is the part worth examining closely, because the science is messier than a two-option menu suggests.

Does the science back this up?

Partially, but with significant caveats. Tesamorelin's visceral fat claim is the strongest ground he stands on. Sermorelin's "re-teaches" mechanism is a reasonable but oversimplified description. The clean binary he draws between the two is where he loses scientific credibility.

Tesamorelin is an FDA-approved synthetic analogue of growth hormone-releasing hormone (GHRH), specifically approved for HIV-associated lipodystrophy. The visceral fat reduction data is real. Falutz et al. (2010, New England Journal of Medicine) found significant reductions in visceral adipose tissue in HIV patients, with some metabolic benefit. That's a narrow, specific population, not a general "get shredded" use case.

Sermorelin is a truncated GHRH analogue. The idea that it "reminds your body" to produce GH is a loose but not entirely wrong description of its mechanism as a GHRH receptor agonist. However, clinical evidence for sermorelin's benefits in sleep quality and anti-aging in otherwise healthy adults is sparse. Walker et al. (1996, Journal of Clinical Endocrinology and Metabolism) documented GH pulse stimulation, but robust long-term outcome data in healthy populations simply does not exist at the scale Grant implies.

What did they get wrong (or right)?

He got the directional mechanism roughly right. He got the clinical evidence picture wrong by omission, and the marketing wrapper around it is a real problem.

Credit where it's due: tesamorelin does have a stronger, more direct GHRH signal than sermorelin, and there is legitimate published data on visceral fat reduction. Calling sermorelin "more gentle" is a reasonable lay description of its lower potency and shorter half-life.

But "never look over 40" is not a clinical claim, it's an anti-aging fantasy that has no controlled trial support in healthy adults. Presenting a three-month before-and-after photo of one client named Steve as evidence for a peptide recommendation is anecdote dressed as data. The GHK-Cu pairing recommendation is almost entirely speculative for the claimed benefits, with most evidence limited to in vitro wound-healing studies (Pickart, 2008, Journal of Biomaterials Science).

The "hard R" stack recommendation with tesamorelin, delivered casually to 31,000 viewers with zero health screening, is irresponsible. Stacking GHRH analogues amplifies IGF-1 signaling, which carries real risks including insulin resistance and, theoretically, promotion of existing malignancies.

What should you actually know?

These are prescription compounds in the United States, not supplements. That matters enormously for how you evaluate advice from a TikTok account.

Tesamorelin is FDA-approved as Egrifta for a specific indication. Sermorelin is available by prescription and used off-label in some functional medicine contexts. Neither is legal to sell, dispense, or recommend without a licensed prescriber involved in your care. A DM-based "cheat sheet" from a one-on-one client practice does not constitute medical supervision.

Anyone considering either peptide should have baseline labs including IGF-1, fasting insulin, and a lipid panel, reviewed by a licensed provider who knows their full medical history. People with active malignancy, pre-diabetes, or certain cardiovascular conditions face real risks from GH-axis stimulation that a TikTok decision tree cannot screen for.

• Tesamorelin's visceral fat data comes from HIV patients, not healthy adults seeking body recomposition.
• Sermorelin's anti-aging benefits in healthy adults lack large, controlled trial support.
• Both compounds require a valid prescription and medical oversight in the US.
• The GHK-Cu pairing for sermorelin has no clinical outcome data supporting the specific claims made here.